Sign in
SVRA Stock Price, Chart, Stats & News
Savara Inc.
Save
1.17B
Market cap
–
Current P/E
0.41x
Forward P/E
SVRA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -46.89% |
ROE | -84.01% |
D/E | 0.15x |
Interest coverage ratio | – |
SVRA valuation
P/E | – |
P/S | – |
P/B | 5.63x |
P/CF | -11.31x |
P/FCF | -10.41x |
P/OCF | -11.31x |
PEG | -5.19x |
EV multiple | -8.66x |
About
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis.
Similar securities
Based on sector and market capitalization
Report issue